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hemistry DepartmAbstract Cytochrome P450 (CYP)-mediated epoxidation of arachidonic acid (AA) contributes to
important biological functions, including the pain-relieving responses produced by analgesic drugs.
However, the relevant epoxygenase(s) remain unidentiﬁed. Presently, we describe the tissue distribution,
high-throughput assay, and pharmacological characteristics of the rat epoxygenase CYP2C24. Following
cloning from male rat liver, recombinant baculovirus containing the C-terminal His-tagged cDNA was
constructed and used to express the protein in Spodoptera frugiperda (Sf9) cells. Enzymatic activity was
detected with membranes, NADPH regenerating system and CYP reductase, and optimized for high
throughput screening by use of the Vivid Blue& BOMCC ﬂuorescence substrate. Quantitative real-time
PCR identiﬁed CYP2C24 m-RNA in liver, kidney, heart, lung, gonad and brain. Screening of CYP2C24
activity against a panel of inhibitors showed a very strong correlation with activity against the human
homologue CYP2C19. In agreement with recent ﬁndings on CYP2C19, the epoxygenase blockers PPOH
and MS-PPOH inhibited CYP2C24 only weakly, conﬁrming that these drugs are not universal
epoxygenase inhibitors. Finally, comparisons of the CYP2C24 inhibitor proﬁle with anti-analgesic
activity suggests that this isoform does not contribute to brain analgesic drug action. The present methods
and pharmacological data will aid in study of the biological signiﬁcance of this CYP isoform.
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Jun Yang et al.1381. Introduction
The metabolism of arachidonic acid (AA) by cyclooxygenases,
lipoxygenases and/or epoxygenases leads to production of
many mediators, including prostanoids, thromboxanes, leuko-
trienes, hepoxillins, hydroxyeicosatetraenoic acids (HETEs)
and epoxyeicosatrienoic acids (EETs)1. Many cytochrome
P450 monooxygenases (CYPs) participate in these pathways
by catalyzing AA hydroxylation and/or epoxidation to pro-
duce HETEs and EETs2. CYP-derived eicosanoids are
thought to perform a variety of important biological func-
tions, including regulation of ion transport, cellular prolifera-
tion, apoptosis, inﬂammation, and hemostasis3. More recent
studies have implicated AA epoxygenase products in other
functions, including vascular regulation4,5, neurovascular dila-
tion6, and analgesic drug action7–9. However, many of the
biologically relevant epoxygenases have not been identiﬁed,
especially in the brain.
Members of several CYP subfamilies can perform AA
epoxidation, including CYP1A, CYP2B, CYP2C, CYP2D,
CYP2E, CYP2N, CYP2G, CYP2J, CYP4A and CYP4X10–16.
Of these, the CYP2C subfamily is the largest17, yet informa-
tion is lacking on many CYP2C isoforms. CYP2C24, a rat
CYP2C isoform cloned in 199118,19 is closely related to rat
CYP2C11 (75% homology), rat CYP2C6 (72%), human
CYP2C18 (78%) and human CYP2C19 (74%). Although
CYP2C24 was reported to be the second-most abundant
CYP2C isoform in the kidney17, little is known about this
particular isoform. CYP2C24 was detected by Northern
analysisin rat kidney, liver and prostate19, but the existence
of this enzyme in other tissues is not known. Recombinant
CYP2C24 was reported to catalyze AA metabolism to mix-
tures of epoxy- and monohydroxylated acids, implying an
epoxygenase role for this enzyme20. However, we are unaware
of any other information on substrates, inhibitors, or meth-
odologies for the study of this enzyme. Presently, we demon-
strate the existence of CYP2C24 in the rat brain, describe the
development of a high-throughput screening method utilizing
baculovirus-expressed enzyme, and report the effects of inhibitors
on this enzyme.2. Materials and methods
2.1. Materials
7-Dimethylamino-4-triﬂuoromethylcoumarin (C152), 4-, 4
"
-
biphenylaldehyde (4-BA), 7-ethoxy-4-triﬂuoromethylcoumarin
(EFC), Vivid& BOMCC substrate (3-cyano-7-(benzyloxy-
methoxy)-coumarin), and Vivid Blue& ﬂuorescent standard
(3-cyano-7-hydroxy-coumarin) were purchased from Invitrogen
(Carlsbad, CA). Methoxy-4-triﬂuoromethylcoumarin (MFC), 7-
hydroxy-4-triﬂuoromethylcoumarin, dibenzylﬂuorescein (DBF)
and cDNA-expressed P450s (CYP2C8, CYP2C9) were purchased
from BD Bioscience (Woburn, MA). Acetonitrile (HPLC grade)
and magnesium chloride hexahydrate were purchased from Fisher
Scientiﬁc (Pittsburgh, PA). Sulconazole, quercetin and ticlopidine
were purchased from Krackeler Scientiﬁc, Inc. (Albany, NY).
Miconazole and ﬂuconazole were purchased from MP Bioscience
(Buxton, UK).N-(Methylsulfonyl)-2-(2-propynyloxy)-benzenehex-
anamide (MS-PPOH) and 2-(2-propynyloxy)-benzenehexanoic
acid (PPOH) were purchased from Cayman Chemicals (AnnArbor, MI). CC12 [4(5)-((4-iodobenzyl)thiomethyl)-1H-imida-
zole21] and MW06-25 [N-((4-iodobenzyl)thiomethyl)-imida-
zole8] were available from laboratory stock. Enzyme assays
were conducted in black Costar 96-well plates (Corning
Incorporated, Corning, NY). All other reagents were pur-
chases from Sigma-Aldrich (St. Louis, MO).
2.2. Animal and tissue preparation
Male and female Sprague Dawley rats (250–315 g, Taconic
Farms, Germantown, NY) were euthanized with CO2, and
tissues were rapidly removed. Total RNA from brain, liver,
kidney, lung, heart and gonads was isolated by Trizol
(Invitrogen) and ﬁrst-strand DNA was synthesized using the
First-Strand kit (Invitrogen) according to the manufacturer’s
instructions.
2.3. Construction of expression plasmids
The full coding region of CYP2C24 was ampliﬁed by poly-
merase chain reaction (PCR) from male rat liver cDNA using
the forward primer 5
"
-ATGGATCCAGTCCTGGTCCT-3
"
and the reverse primer 5
"
-TTAACGAGGAATGAAGCA-
CAGC-3
"
. These primers were designed based on the nucleo-
tide sequence ﬁrst reported for CYP2C24 cDNA (GenBank
accession no. M86677). The reaction mixtures (50 mL) con-
tained 0.2 mM dNTPs, 1 mM MgSO4, 1 U of phusion DNA
polymerase (NEB, Ipswich, MA) and each oligonucleotide
primer at 0.5 mM. PCR consisted of 35 cycles of denaturation
at 98 1C for 10 s, annealing at 65 1C for 10 s and extension at
72 1C for 45 s. The initial denaturation was performed at
98 1C for 30 s. The ampliﬁed product (1500 bp) was puriﬁed
with a gel extraction kit (Qiagen, Valencia, CA), and the
puriﬁed PCR products were ligated into pGEM-T (Promega,
Madison, WI) and sequenced. The full-length cDNA
thus obtained was modiﬁed by PCR ampliﬁcation with
5
"
-ATGGATCCAGTCCTGGTCCT-3
"
and 5
"
-GCTCTAGAT-
TAACGAGGAATGAAGCACAGC-3
"
as primers under
the conditions described above. XbaI was introduced to the
3
"
-end of the stop codon to facilitate subcloning into the
XbaI and EheI of the insect expression vector (pFASTBAC
HTA). Three plasmids were constructed for expression and
further study: pFASTBAC CYP2C24, pFASTBAC
CYP2C24N (His tag on the N-terminal of CYP2C24)
and pFASTBAC CYP2C24C (His tag on C-terminal end
of CYP2C24). pFASTBAC 2C24 was constructed from
2C24N by inverse PCR using two primers (forward primer
5
"
-ATGGATCCAGTCCTGGTCCT-3
"
and the reverse
primer 5
"
-GGTTTCGGACCGAGATCCG-3
"
). pFASTBAC
2C24C was constructed by adding the His tag through the
KpnI and BamHI sites. All plasmids were sequenced.
2.4. Expression of recombinant CYP2C24
The cDNAs coding for CYP2C24 were expressed using a
BAC-TO-BAC Baculovirus Expression System (Invitrogen),
following the manufacturer’s instructions. Recombinant CYP
baculoviruses were used to infect Sf9 insect cell cultures in the
presence of 0.2 mM hemin. Infected cells were harvested at
around 72 h postinfection, the membrane fraction was obtained as
described previously22,23. In brief, the Sf9 cell pellet was
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buffer containing 100 mM Tris-acetate buffer (pH 7.4),
150 mM KCl and 1 mM EDTA. The nuclear fraction and
unbroken cells were removed by centrifugation at 100 g for
10 min at 4 1C. The supernatant fraction was then centrifuged
at 100,000 g for 90 min at 4 1C. Pellets were then suspended
in membrane storage buffer (50 mM Tris-acetate, pH 7.4, 20%
glycerol and 0.1 mM EDTA). CYP2C24 expression levels were
determined by CO-difference spectroscopy and Western blot
with HisProbe-HRP reagent (Pierce, Rockford, IL).
2.5. Real-time analysis of CYP 2C24 expression
RNA preparation and ﬁrst-strand DNA synthesis from
male and female organs were performed as described above.
One mL cDNA was used as the template for each PCR.
Primers for real-time PCR of rat CYP2C24 mRNA were
forward: 5
"
-CGCTCATTGCCGATAGTG and reverse: 5
"
-
CGCTTTCCTGTTGAGAAAGG, speciﬁcally amplifying a
245 bp fragment of the cDNA. Primers for beta-actin were
(forward: 5
"
-AGGGAAATCGTGCGTGAC and reverse: 5
"
-
CGCTCATTGCCGATAGTG, speciﬁcally amplifying a
145 bp fragment of the cDNA. Quantitative real-time PCR
was performed using ABsoluteSYBR Green PCR Master Mix
according to the manufacturer’s instructions (Thermo scien-
tiﬁc, USA). Each cDNA sample was analyzed in duplicate.
Real-time RT-PCR (25 mL) was performed with 70 nM for-
ward and reverse primers and 1 mL ﬁrst-strand cDNA tem-
plate. The program was set at 95 (15 min), followed by 95 1C
(20 s) for 45 cycles, 58 1C (20 s) and 72 1C (20 s). Real-time
PCR was performed on a MyIQ Single-Color Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). CYP 2C24
mRNA levels were calculated using the comparative Ct
method and normalized to beta-actin expression levels.
2.6. Measurements of CYP2C24 enzyme activity
Stock concentrations of substrates were dissolved in 100%
acetonitrile, with a ﬁnal concentration of 0.75% (v/v) in the
incubation mixture. Reaction mixtures containing NADPH-
regenerating system (0.14 mM NADPþ, 0.37 mM D-glucose-6-
phosphate, 0.04 U/mL glucose-6-phosphate dehydrogenase,
and 0.37 mM magnesium chloride) in 50 mM Tris buffer
(pH 7.4) were pre-incubated at 37 1C for 15 min in a total
volume of 0.1 mL. Reactions were initiated by the addition
(0.1 mL) of CYP2C24 or CYP2C24C, rat P450 oxidoreductase
insect control (BD Biosciences, 1 mg) and substrate mixture in
Tris buffer (pH 7.4) followed by incubation of a total volume
of 0.2 mL at 37 1C. For kinetic studies, ﬂuorescent CYP
products were measured in real time with a Victor 3140
Multilabel Counter (Perkin Elmer, Waltham, MA) at
405 nm (excitation) and 460 nm (emission). Incubations for
sample blanks used boiled enzyme. Signals from sample
blanks were subtracted from all sample values. Product
formation was linear for 20 min when using Vivid& BOMCC
substrate. Product concentrations were calculated from cali-
bration standard curves of the Vivid& Blue ﬂuorescent stan-
dard. Kinetic parameters were calculated by non-linear
regression ﬁtting to the Michaels–Menton equation for a
single enzyme model using Prism 5.0 software (GraphPad
Software Inc., San Diego, CA).2.7. IC50 determinations for CYP2C24
IC50 values were estimated according to the method of Crespi
et al.24. Reaction mixtures containing NADPH-regenerating
system were prepared as described above and mixed with
inhibitors (from stock concentrations in 100% acetonitrile,
diluted to a ﬁnal concentration of 0.75% acetonitrile). Follow-
ing pre-incubation at 37 1C for 15 min, reactions were initiated
by the addition of CYP2C24C and BOMCC (10 mM ﬁnal
concentration), followed by incubation at 37 1C for 20 min
and ﬂuorescent product determination as described above. For
time-dependent inhibition studies, inhibitors were pre-incu-
bated in 50 mM Tris (pH 7.4) with enzyme and regenerating
system for 0, 15 or 30 min. Substrate was then added, and
samples were incubated at 37 1C for an additional 20 min.
IC50 values were calculated by non-linear regression using the
Prism 5.0 sigmoidal dose–response curve function. Statistical
analysis of time-dependent inhibition experiments were per-
formed by two-factor analysis of variance (ANOVA,
Prism 5.0).
2.8. Measurements of human (CYP2C8, CYP2C9, and
CYP2C19) enzyme activities
Human CYP assays (1 pmol per well) were carried out in
a total volume of 0.2 mL of 50 mM potassium phosphate
buffer (pH 7.4) containing 1% acetonitrile. CYP2C9 activity
(1 pmol) was determined with MFC (75 mM) as substrate and
incubated at 37 1C for 30 min as described24. CYP2C19 and
CYP2C8 (both 1 pmol, 0.5 mM DBF) were assayed identically
to the method described25 for CYP2C11. Brieﬂy, inhibitors (in
100% acetonitrile) were added to the reaction mixtures
containing NADPH-regenerating system (ﬁnal concentrations
of 1.3 mM NADPþ, 3.3 mM D-glucose-6 phosphate, 0.4 U/mL
glucose-6-phosphate dehydrogenase, and 3.3 mM magnesium
chloride) in 0.1 mL buffer, followed by pre-incubation at
37 1C for 15 min. Reactions were initiated by the addition of
0.1 mL solution containing enzyme and DBF in buffer,
incubated at 37 1C for 30 min, and terminated by the addition
of 75 mL of 2 M NaOH, followed by a 2 h post incubation at
37 1C. Product formation was determined from a ﬂuorescein
standard curve, prepared by spiking ﬂuorescein into the blank
incubation mixture. Excitation ﬁlter 485 nm (bandwidth
14 nm) and emission ﬁlter at 535 nM (bandwidth 25 nm) were
used to monitor ﬂuorescein formation.3. Results
3.1. Expression of CYP2C24 protein in Sf9 cells
The CYP2C24 cDNA was cloned from male liver based on the
sequence of the gene18,19 through a primer polymerase chain
reaction strategy. The deduced 490 amino acid sequence was
identical with that published previously (GenBank accession No.:
P33273) with the exception of Leu-Val substitution at
residue 112.
Membrane fractions from Sf9 cells expressing CYP 2C24C
were analyzed by reduced CO-difference spectroscopy (Fig. 1,
left panel). The spectrum showed the typical Soret peak at
450 nm and a slight peak at 420 nm. No P450 was detected by
this method in membrane fractions from control cells or cells
Figure 1 Characteristics of rCYP2C24C. Left: Reduced CO-
difference spectrum of membrane fraction from Sf9 expressing
CYP2C24C. Right: Western blot of rCYP2C24C (10 mg protein)
was detected by HisProbe-HRP. Lane 1, CYP2C24C; lane 2, Sf9
microsomes infected by wild type baculovirus.
Figure 2 Tissue distribution of CYP2C24 mRNA in male and
female adult rats measured by real-time PCR. mRNA levels are
expressed as the ratio of CYP2C24 to beta-actin levels in each tissue,
normalized to rat male brain (i.e. CYP2C24/b-actin¼1). Each column
represents the mean (7SEM) from four measurements.
Figure 3 Substrate–velocity curves for the oxidation of BOMCC
by CYP2C24 and CYP2C24C. Recombinant enzymes (CYP2C24
and CYP2C2C24C, 20 mg each) isolated from 2000g pellets were
incubated as described at 37 1C for 20 min. Product formation
(ordinate, pmol product/mg enzyme/min) is shown at each
concentration of substrate (abscissa). Each data point represents
the mean7SEM of values determined in triplicate. Results for the
two enzymes were identical. Km and Vmax values, estimated by
non-linear regression for the pooled results, are shown.
Jun Yang et al.140infected with the wild-type virus (not shown). A Western blot
of Sf9 cells expressing CYP 2C24C exhibited a single protein
band (lane 1) with an approximate molecular weight of
56.9 kD. No bands were seen from the wild type baculovirus
infected Sf9 cells (lane 2). Approximately 70% of the
CYP2C24 was found in the membrane fraction, with the
remainder in the fraction containing unbroken cells and
nuclei. The yield of CYP2C24 from CYP2C24N virus-infected
Sf9 cells was much less than that from recombinant
CYP2C24C virus-infected Sf9 cells (not shown).3.2. Real-time analysis of CYP2C24 expression
The presence of CYP2C24 mRNA was examined in several rat
tissues from both genders. Results (Fig. 2) showed highest
CYP2C24 levels in liver and kidney of both sexes, but the
enzyme was also detected in brain, lung, heart and gonads.
Expression levels were low in brain. In liver, kidney and
gonads, CYP2C24 expression was much higher in male than in
female rats. This difference was reversed in heart, in which
females showed higher expression. Sex differences in CYP2C24
expression were not evident in brain.3.3. Kinetics of CYP2C24 activity
In order to develop a high-throughput method for measuring
CYP2C24C activity, several known ﬂuorescent substrates
for CYP2C enzymes (BOMCC, DBF, 4-BA and C152) were
evaluated. Under optimized conditions, BOMCC yielded
the highest signal/noise ratio (6.0 under the conditions
described). Using these speciﬁed conditions, kinetic studies
of CYP2C24 and 2C24C at varying BOMCC concentrations
(1–30 mM) were performed (Fig. 3). Fitted kinetic parameters
for BOMCC oxidation by CYP2C24 were: Km¼13.1271.28 mM
and Vmax¼141.977.0 min1. The Km and Vmax values estimated
for CYP2C24C were 13.9571.78 mM and 145. 179.6 min1.
There were no signiﬁcant differences in Km and Vmax value
between CYP2C24 and CYP2C24C.3.4. Pharmacological inhibition of CYP2C24
A variety of CYP inhibitors were studied on CYP2C24C activity
(Fig. 4, Table 1). Inhibitory activities ranged from extremely
potent (CC12 and MW06-25, IC50 values 25 nM), to moderate
(miconazole and sulconazole, 200 nM), to low (quercetin,
sulfaphenazole, ﬂuconazole and ticlopidine, 5–116 mM). The
epoxygenase inhibitors MS-PPOH and PPOH were also tested
on CYP2C24C (Fig. 5). Concentration–activity curves showed
that both drugs had extremely low potencies, with estimated IC50
values greater than 300 mM (Fig. 5, Table 1). However, varia-
tions in pre-incubation times and the use of very large drug
concentrations found time-dependent inhibition by both drugs.
For PPOH, a two-factor (concentration, time) ANOVA found
signiﬁcant (Po0.001) main effects for both factors. Fitted PPOH
IC50 values were 525, 515, and 408 mM, after 0, 15 and 30 min
pre-incubation times, respectively. Identical ANOVA results
were obtained in the MS-PPOH experiments. Fitted MS-PPOH
Figure 4 Inhibition of CYP2C24 activity by imidazole-contain-
ing drugs. Recombinant CYP2C24 was incubated with substrate
and regenerating system in the presence of varying concentrations
of inhibitors at 37 1C. Percent control activity (ordinate) is shown
at the log of each concentration of inhibitor (abscissa). Each data
point represents the mean (7S.E.M.) of 3 determinations. IC50
values, estimated by non-linear regression, are given in parenth-
eses and in Table 1.
Table 1 Inhibitor potencies on CYP2C24 and related
CYP2C isoforms.
Drug IC50 (mM)
CYP2C24a CYP2C8 CYP2C9 CYP2C19
CC12 0.017 2.767b 0.059b 0.038c
MW06-25 0.029 0.566b 0.155b 0.037c
Sulconazole 0.196 0.262b 0.02d 0.063b
Miconazole 0.191 0.442b 2.4d 0.046c
Fluconazole 5.4 4200e 19–22f 2.959c
Quercetin 28 3.50g 3.14h 6.23h
Ticlopidine 63.1 NT 26.4i 0.368i,
4.3j
Sulfaphenazole 116.1 NT 0.84j,
0.29h
4500k
PPOH 4300 NT 23l 300l
MS-PPOH 4300 15m 11l 480l
IC50 values for the inhibitors (left) are summarized from
current results and relevant literature. NT, not tested.
aNew results (Figs. 4 and 5).
bUnpublished results from this lab (from triplicates).
cConroy et al.8.
dZhang et al.44.
eWinter and Unadkat45.
fKunze et al.46.
gWalsky and Gaman47.
hZou et al.48.
iKo et al.49.
jUsmani et al.50.
kMarques-Soares et al.51.
lVanAlstine and Hough.25.
mBrand-Schieber et al.39.
Figure 5 Inhibition of CYP2C24 activity by PPOH (top) and
MS-PPOH (bottom). Recombinant CYP2C24 was preincubated
with reductase, regenerating system, and the speciﬁed concentra-
tions of inhibitors in 50 mM Tris buffer (pH 7.4) at 37 1C.
Following the speciﬁed preincubation time (t¼0, 15 or 30 min),
samples received substrate (BOMCC, 10 mM) and were incubated
at 37 1C for an additional 20 min. Percent control activity
(ordinate) is plotted vs. the log of each concentration of inhibitor
(abscissa). Each data point represents the mean7S.E.M. of
triplicate values. IC50 values, estimated by non-linear regression,
are given in parentheses for each condition.
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incubations times.4. Discussion
CYP2C enzymes comprise the most complex P450 subfamily
in humans and rodents. The human group, consisting of four
members (CYP2C8, CYP2C9, CYP2C18, and CYP2C19),
metabolize endogenous fatty acids26–28, as well as several
clinically-important drugs17,29–31. In rats, CYP2Cs constitute
approximately 20% of the total liver CYPs17, but much less is
known about the thirteen members of this subfamily (along with
CYP2C24, they are CYP2C6, 2C7, 2C11, 2C12, 2C13, 2C22,
2C23, 2C77, 2C79, 2C80, 2C81, and 2C82). Six of these (2C6,
2C7, 2C11, 2C12, 2C13, 2C23) have previously been reported to
exist in the brain.32,16 The present experiments were performed to
develop methods to study CYP2C24, to search for its expression
in the brain, and to gain speciﬁc pharmacological data on this
enzyme.
The nucleotide sequence presently cloned from rat liver closely
matches that described earlier18,19, conﬁrming the identity of this
product as CYP2C24 (GenBank accession No.: P33273). As
expected, this gene encodes a protein of 490 amino acids, and
contains the P450 heme-binding signature (FSTGKRMCVG). It
should be noted that GenBank identiﬁes this accession number as
Cytochrome P450 CYP2C55, with CYP2C24 given as an alternate
name. Although CYP2C55 is a recognized isoform in the mouse,
expert sources do not use the CYP2C55 name for rat P33273 (e.g.
http://drnelson.uthsc.edu/CytochromeP450.html).
Figure 6 Correlations between inhibitor potencies on CYP2C24
and potencies on human CYP2C isoforms. IC50 values for ten
inhibitors on CYP2C24 are plotted (abscissa, log scale) against
IC50 values for the same drugs determined CYP2C19, CYP2C9,
and CYP2C8 (ordinate, log scale). For each pair of CYPs plotted,
values were analyzed by the Spearman rank correlation test.
Dashed line indicates the theoretical perfect correlation. Outliers
in each correlation are identiﬁed by drug abbreviation (sulc,
sulconazole; ﬂu, ﬂuconazole; ticl, ticlopidine, sulf, sulfaphenazole).
For example, a near-perfect correlation was observed between
potencies on CYP2C24 vs. potencies on CYP2C19 except for ticl,
which is approximately 30-fold less potent on CYP2C24. All data
are from Table 1. Mean values are plotted when the table gave
more than one value. For plotting and correlational analyses,
values in the table estimated to be larger than 200 mM were
arbitrarily designated as 300 mM.
Jun Yang et al.142Incorporation of His tags into CYP2C24 can streamline the
detection and puriﬁcation of this protein. As mentioned, place-
ment of the His tag on the N-terminal of CYP2C24 dramatically
decreased protein expression, as compared with the untagged
plasmid. In contrast, incorporation of the His tag on the C-
terminal did not change expression levels or enzyme activity
(Fig. 4). These ﬁndings suggest that the hydrophobic N-terminal
segment may be important for the proper folding and assembly
of this CYP. This conclusion apparently does not apply to all
CYPs, since the addition of a His tag to the N-terminal of
CYP2C2 increased protein expression33. Holla et al.20 used the
baculovirus/sf9 system for the heterologous expression of
CYP2C11, CYP 2C23 and CYP2C24. These authors did not
incorporate His tags into any of the plasmids, but did note much
lower expression levels for CYP2C24 as compared with the other
two enzymes. The presently-demonstrated expression and activ-
ity of CYP2C24C show this plasmid to be useful for additional
puriﬁcation and study of this enzyme.
The present detection of CYP2C24 mRNA in male rat liver
and kidney (Fig. 2) conﬁrms an earlier Northern analysis18.
This study identiﬁed CYP2C24 mRNA in male, but not
female, adult kidney, consistent with a 30-fold higher level in
male kidney seen presently. The same paper18 found no such
sex difference in liver expression of this mRNA, in stark
contrast with the present results. Gender differences in
expression levels of other CYP2C enzymes are well known,
with the best examples being the male-speciﬁc CYP2C11,
CYP2C13, and CYP3A2, and the female-speciﬁc CYP2C1234.
The existence of CYP2C24 mRNA in lung, heart, gonad and
brain (Fig. 2) has not been previously reported. These ﬁndings
suggest the possibility that this enzyme has functional sig-
niﬁcance in the brain and/or other organs studied. A reverse
gender difference (i.e. female greater than male) in CYP2C24
levels in the heart (Fig. 2) has also not been reported
previously, and requires further study.
In vitro studies of CYP activity have often been hampered
by low enzyme activity, poor solubility of substrates and
sometimes high background ﬂuorescence35. In the only prior
study of CYP2C24 activity, measurements of AA epoxidation
by this enzyme showed very low activity20; such a reaction
cannot presently be monitored by high-throughput methods.
Our results, showing that CYP2C24 activity can be efﬁciently
measured by use of the Vivid& BOMCC reagent in 96-well
plates, demonstrate a reliable, high-throughput method for
studying this enzyme. This substrate has been used success-
fully to measure the activity of CYP2C1935 and several other
CYP isoforms (see http://www.invitrogen.com.cn/downloads/
O-13873-r1_US_0405.pdf).
Pharmacological characterization of CYP2C24 could ulti-
mately help to understand its biological signiﬁcance. The list
of inhibitors studied presently (Table 1) includes drugs with
reported selectivity towards CYP2C9 (sulfaphenazole), 2C19
(ticlopidine, ﬂuconazole), and CYP2C8 (quercetin), as well as
less selective inhibitors. The CYP epoxygenase inhibitors
(PPOH and MS-PPOH) were also studied. Finally, the list
also includes CC12 and MW06-25, two imidazole-containing
CYP inhibitors found to block analgesic activity in the
brain8,36. Activities on CYP2C24 were compared (Table 1)
and correlated (Fig. 6) with relative activities on three other
CYP2C isoforms. Although it is recognized that inhibitor Ki
(vs. IC50) values would be most valuable in making compar-
isons across enzymes, many of the studies cited in Table 1 didnot report information sufﬁcient for Ki calculations. Further-
more, the mechanisms of action of most of these inhibitors are
not known.
Activity of the compounds on CYP2C24 was very highly
correlated with activity on CYP2C19 (Fig. 6, r¼0.93, Po0.01).
These ﬁndings, showing strong pharmacological similarities
between the enzymes, are consistent with their high sequence
homologies (74%), and conﬁrm that rat CYP2C24 closely
resembles human CYP2C19. Notable similarities in inhibitor
actions include CC12 and MW06-25 (very potent on both), and
PPPOH (very low activity on both, further discussed below).
CC12 is not a selective CYP2C24/CYP2C19 inhibitor, since
it was shown to block 16 human CYPs in the 12–500 nM
concentration range37. MW06-25 may have more selectivity,
but less is known about the CYP inhibitory proﬁle of this
compound8. The single outlier in the CYP2C24–CYP2C19
correlation was ticlopidine, which was 16–160-fold less active
on CYP2C24. Inhibition of CYP2C24 was also signiﬁcantly
correlated with activity on CYP2C9 (Fig. 6, r¼0.71, Po0.05).
Notable outliers in this correlation were sulfaphenazole and
sulconazole, which were much less active on CYP2C24 as
compared with CYP2C9. Among the enzymes studied, the
inhibitor proﬁle on CYP2C24 was least correlated with the
activity on CYP2C8. CC12 and ﬂuconazole were considerably
less potent on CYP2C8 than predicted from their actions on
CYP2C24. Taken together, these results show that CYP2C24
has a CYP2C-like proﬁle, but no highly selective inhibitors of
this enzyme were identiﬁed.
The acetylenic fatty acid derivatives PPOH and MS-PPOH
were initially characterized as selective inhibitors of AA epox-
ygenase (vs. AA hydroxylase) in renal cortical microsomes38,39.
Best known CYP epoxygenase targets for one or both of these
drugs are CYP4A2, CYP4A340, and CYP2C839. PPOH and MS-
PPOH have been used extensively in CYP epoxygenase research,
P450 2C24: Expression, tissue distribution, high-throughput assay, and pharmacological inhibition 143and, although these drugs have been widely assumed to be
general inhibitors of all CYP epoxygenases, a recent study found
this to not be the case25. Predictably, PPOH was found to be a
potent inhibitor of the epoxygenases CYP2B1 and CYP2C9, but
only a moderate inhibitor of CYP2B6 and CYP2C11. Surpris-
ingly, however, this drug only weakly inhibited the epoxygenases
CYP2C6 and CYP2C1925 (see also Table 1). As compared with
PPOH, MS-PPOH inhibited even fewer epoxygenases, with only
very weak activity on CYP2B625. Since CYP2C24 was previously
reported to have AA epoxygenase activity20, it was of interest to
assess the inhibitory activity of these drugs on CYP2C24. The
present results, showing very low activity of PPOH and MS-
PPOH on CYP2C24, provide additional similarities between this
enzyme and CYP2C19 (Table 1). Furthermore, these ﬁndings
support the conclusion25 that PPOH and MS-PPOH do not
inhibit all CYP epoxygenases.
Terminal acetylenic fatty acids (such as PPOH and MS-
PPOH) have been proposed to function as ‘‘suicide sub-
strates’’, also known as mechanism-based inhibitors41. Such
compounds are presumed to undergo enzymatic oxidation,
followed by enzyme inactivation, producing a long-acting,
irreversible inhibition of activity. It is important to establish
whether these compounds act by such a mechanism, since
these drugs may act at both CYP and non-CYP targets42. A
mechanism-based action, if veriﬁed, would only be expected
on the CYP targets. Our lab25 recently reported time- and
NADPH-dependent inhibition of CYP2C6, CYP2C9
CYP2C11, and CYP2B1 by PPOH and MS-PPOH, consistent
with mechanism-based inhibition of these enzymes. Although
the present results found these drugs to be very weak
inhibitors of CYP2C24, the time-dependent inhibition of this
enzyme by both PPOH and MS-PPOH (Fig. 5), is consistent
with this mechanism.
Our laboratory became interested in brain CYPs through
studies of the CNS pain-relieving properties of the histamine
H2 receptor antagonist cimetidine, and its non-H2-acting
congener improgan43. Searching for the analgesic targets of
these drugs, we characterized in detail the high afﬁnity binding
of 3H-cimetidine (3H-CIM) in rat brain homogenates37. High
afﬁnity 3H-CIM binding in brain was unrelated to the
histamine H2 receptor, but showed strong biochemical simila-
rities to a heme-containing CYP protein. Potent inhibition of
the binding by the CYP2C19 inhibitor tranylcypromine sug-
gested that the rat brain 3H-CIM-binding protein(s) resemble
human CYP2C19. However, 3H-CIM did not bind to recombi-
nant CYP2C19, to seven other human CYPS, or to three rat
CYPs (2B1, 2C6, and 2C11)37. The authors concluded that
3H-CIM binds to one or more unidentiﬁed CYP proteins in the
rat brain37. Since the pharmacology of 3H-CIM binding in rat
brain resembles that of human CYP2C19, the similarities
between CYP2C24 and CYP2C19 (Fig. 6) suggested the
possibility that brain CYP2C24 accounted for 3H-CIM in the
rat brain. However, the present results do not support this
hypothesis, since ticlopidine, sulfaphenazole and quercetin (all
inhibitors of CYP2C24, Table 1) were completely inactive on
the rat brain binding at 100 mM37. Furthermore, unpublished
studies in our lab did not detect 3H-CIM binding in prepara-
tions of CYP2C24C when tested as described37. Thus, the
3H-CIM-binding protein in rat brain (likely to be a CYP)
remains to be identiﬁed.
Recent studies from our laboratory used transgenic and
pharmacological approaches to show that one or more brainCYPs is essential in signal transduction pathways following
administration of either opioid8 or non-opioid (i.e. impro-
gan)36 analgesic drugs. Support for the hypothesis that these
analgesic drugs (acting through difference receptors) activate
pain-relieving circuits through stimulation of AA epoxidation
has been summarized8,36. The ﬁndings include inhibition of
analgesia by general CYP inhibitors and by MS-PPOH, but
studies to date have not identiﬁed the relevant CYP epox-
ygenase(s). The present pharmacological characterization of
CYP2C24 (Table 1) is useful for assessing the importance of
this enzyme for analgesic mechanisms. For improgan analge-
sia, detailed in vivo dose–response curves show a rank order of
inhibitory activity (most to least potent) to be MS-PPOH4
ﬂuconazole4miconazole4MW06-254CC1236. Since Table 1
shows nearly the exact opposite potency rank for these
compounds acting on CYP2C24, the present ﬁndings make
highly unlikely that this brain enzyme contributes to improgan
analgesia. In vivo pharmacological data on inhibition of opioid
analgesia is much less complete, but ongoing and published
studies8,21 suggest a probable rank order of inhibitory activity
against morphine action to be MW06-254MS-PPOH4CC12,
also distinct from Table 1. These results suggest that
CYP2C24 is unlikely to participate in CNS analgesic drug
action. Additional studies to identify the biological signiﬁ-
cance of CYP2C24 will be facilitated by our present ﬁndings
on the tissue distribution and pharmacological inhibition of
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